[go: up one dir, main page]

PE20040701A1 - Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos - Google Patents

Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos

Info

Publication number
PE20040701A1
PE20040701A1 PE2003000724A PE2003000724A PE20040701A1 PE 20040701 A1 PE20040701 A1 PE 20040701A1 PE 2003000724 A PE2003000724 A PE 2003000724A PE 2003000724 A PE2003000724 A PE 2003000724A PE 20040701 A1 PE20040701 A1 PE 20040701A1
Authority
PE
Peru
Prior art keywords
phenyl
indolinone
medicines
preparation
substituted
Prior art date
Application number
PE2003000724A
Other languages
English (en)
Inventor
Armin Heckel
Gerald Jurgen Roth
Frank Hilberg
Thorsten Lehmann-Lintz
Jorg Kley
Meel Jacobus C A Van
Ulrike Tontsch-Grunt
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10233366A external-priority patent/DE10233366A1/de
Priority claimed from DE10328533A external-priority patent/DE10328533A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20040701A1 publication Critical patent/PE20040701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE X ES O; R1 ES H; R2 ES F, Cl, Br, CN; R3 ES FENILO SUSTITUIDO O NO CON F, Cl, I, ALCOXI, ENTRE OTROS; R4 ES FENILO SUSTITUIDO O NO CON ALQUILO C1-C3, GUANIDINO, MONO- O DI-(ALQUIL C1-C2), ENTRE OTROS; R5 Y R6 SON H. SON COMPUESTOS PREFERIDOS: 3-Z-[1-(4-(DIMETILAMINOMETIL-ANILINO)-1-(3-(2-CARBOXI-ETIL)-FENIL)-METILEN]-6-CLORO-2-INDOLINONA; 3-Z-[1-(4-(N-4-METIL-PIPERAZIN-1-IL-METILCARBONIL)-N-METIL-AMINO)-ANILINO)-1-(4-(2-CARBOXI-ETIL)-FENIL)-METILEN]-6-FLUOR-2-INDOLINONA. SE REFIERE TAMBIEN A UNA COMOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE RECEPTORES TIROSINAS QUINASAS, ASI COMO SOBRE LA PROLIFERACION DE CELULAS ENDOTELIALES Y DIVERSAS CELULAS TUMORALES
PE2003000724A 2002-07-23 2003-07-21 Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos PE20040701A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10233366A DE10233366A1 (de) 2002-07-23 2002-07-23 In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10328533A DE10328533A1 (de) 2003-06-24 2003-06-24 In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PE20040701A1 true PE20040701A1 (es) 2004-11-30

Family

ID=30771725

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000724A PE20040701A1 (es) 2002-07-23 2003-07-21 Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos

Country Status (24)

Country Link
EP (1) EP1523473B1 (es)
JP (1) JP4401291B2 (es)
KR (2) KR20120003025A (es)
CN (1) CN1318403C (es)
AR (1) AR041188A1 (es)
AU (2) AU2003254557B2 (es)
BR (1) BR0312799A (es)
CA (1) CA2493436C (es)
DK (1) DK1523473T3 (es)
EA (1) EA008623B1 (es)
EC (1) ECSP055567A (es)
ES (1) ES2409062T3 (es)
HR (1) HRP20050069A2 (es)
IL (1) IL166404A0 (es)
MX (1) MXPA04012937A (es)
MY (1) MY138141A (es)
NO (1) NO20050937L (es)
PE (1) PE20040701A1 (es)
PL (2) PL374879A1 (es)
RS (1) RS20050047A (es)
SA (1) SA03240430B1 (es)
TW (1) TWI343375B (es)
UY (1) UY27903A1 (es)
WO (1) WO2004009547A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20061155A1 (es) * 2004-12-24 2006-12-16 Boehringer Ingelheim Int Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
EA013239B1 (ru) 2005-04-28 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые соединения для лечения воспалительных заболеваний
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
NZ586760A (en) * 2008-01-25 2011-12-22 Boehringer Ingelheim Int Process for the preparation of 4-[(Z)-[[4-[(dimethylamino)methyl]phenyl]amino](6-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-benzenepropanoic acid
MX2010007950A (es) * 2008-01-25 2010-08-04 Boehringer Ingelheim Int Formas salinas de un derivado de 6-fluoro-1,2-dihidro-2-oxo-3h-ind ol-3-ilideno, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
UY32010A (es) 2008-07-29 2010-02-26 Boehringer Ingelheim Int Nuevas indolinonas, composiciones conteniéndolas y aplicaciones
EP2910547B1 (en) 2012-10-17 2017-06-14 Okayama University Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug
DK2930167T3 (en) * 2012-12-06 2019-02-25 Kbp Biosciences Co Ltd INDOLINO DERIVATIVE AS A TYROSINKINASE INHIBITOR
CN105461609B (zh) * 2015-12-25 2019-08-23 杭州新博思生物医药有限公司 一种尼达尼布的制备方法
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1115704E (pt) * 1998-09-25 2003-11-28 Boehringer Ingelheim Pharma Novas indolinonas substituidas com accao inibidora sobre varias quinases e complexos ciclina/cdk
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
JP2005508336A (ja) * 2001-09-27 2005-03-31 アラーガン、インコーポレイテッド キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類
US6559173B1 (en) * 2001-09-27 2003-05-06 Allergan, Inc. 3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors

Also Published As

Publication number Publication date
SA03240430B1 (ar) 2008-03-23
CA2493436A1 (en) 2004-01-29
TWI343375B (en) 2011-06-11
CN1668589A (zh) 2005-09-14
EA200500148A1 (ru) 2005-08-25
JP2005533841A (ja) 2005-11-10
UY27903A1 (es) 2004-02-27
ES2409062T3 (es) 2013-06-24
HK1081554A1 (en) 2006-05-19
HRP20050069A2 (en) 2005-12-31
EP1523473A1 (de) 2005-04-20
MXPA04012937A (es) 2005-05-16
PL397821A1 (pl) 2012-03-12
AU2010202845A1 (en) 2010-07-22
EP1523473B1 (de) 2013-02-27
BR0312799A (pt) 2005-05-03
RS20050047A (sr) 2007-09-21
JP4401291B2 (ja) 2010-01-20
KR20120003025A (ko) 2012-01-09
PL374879A1 (en) 2005-11-14
KR20050052456A (ko) 2005-06-02
CN1318403C (zh) 2007-05-30
AR041188A1 (es) 2005-05-04
NO20050937L (no) 2005-02-21
AU2003254557A1 (en) 2004-02-09
WO2004009547A1 (de) 2004-01-29
IL166404A0 (en) 2006-01-15
EA008623B1 (ru) 2007-06-29
TW200413314A (en) 2004-08-01
CA2493436C (en) 2011-11-08
MY138141A (en) 2009-04-30
AU2003254557B2 (en) 2010-07-22
DK1523473T3 (da) 2013-06-03
ECSP055567A (es) 2005-04-18

Similar Documents

Publication Publication Date Title
PE20040701A1 (es) Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
RU2004132204A (ru) Имидазоконденсированные соединения
PE20040647A1 (es) Inhibidores de cinasas de tirosina
PE20041080A1 (es) Preparacion de medicamentos derivados de indolina sustituidos con heterociclos
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
CY1112916T1 (el) 3-ζ-1-(4-(ν-((4-μεθυλ-πιπεραζιν-1-υλ)-μεθυλκαρβονυλ)-ν-μεθυλ-αμινο)-ανιλινο)-1-φαινυλ-μεθυλενο-6-μεθοξυκαρβονυλ-2-ινδολινονη-μονοαιθανοσουλφονικη και η χρηση αυτης ως φαρμακευτικη συνθεση
PE20060215A1 (es) 4-fenilamino-quinazolin-6-il-amidas
DE60328010D1 (de) Heterocyclische verbindungen
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
PE20090042A1 (es) Analogos de ciclopamina
PE20110894A1 (es) Derivados de pirimidin indol para el tratamiento de cancer
NO20070122L (no) Quinazolinonderivater anvendelige som vanilloidantagonister
PE20100239A1 (es) Derivados de benzoquinazolina como promotores de la liberacion de hormona paratiroides
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
CO5050296A1 (es) Derivados de 1-arenosulfonil-2-arilo-pirrolidina y de piperidina
TW200745032A (en) Novel heterobicyclic derivatives
MY137761A (en) The use of n-arylhdrazine derivatives for combating non-crop pests
SE0104250D0 (sv) Heterocyclic compounds
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
SE0203303D0 (sv) Novel Compounds
PE20061155A1 (es) Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed